Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Etoricoxib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Spondylitis, Ankylosing 1 Somatoform Disorders 1 Prostatic Neoplasms 1 Peripheral Nervous System Diseases 1 Breast Neoplasms 1 Breast Neoplasm Female 1 Bone Neoplasms 1

Interventions

Docetaxel 291 Prednisone 240 enzalutamide 191 Leuprolide 185 Radiotherapy 178 Abiraterone Acetate 169 Magnetic Resonance Spectroscopy 163 bicalutamide 140 Goserelin 138 Androgen Antagonists 119 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108 Radiosurgery 108 apalutamide 91 gallium 68 PSMA-11 81 abiraterone 80 Specimen Handling 73 darolutamide 65 Surveys and Questionnaires 64 Gonadotropin-Releasing Hormone 62 Triptorelin Pamoate 58 Radiation 57 Biopsy 57 Brachytherapy 53 cabazitaxel 52 Standard of Care 51 Zoledronic Acid 50 Radiotherapy, Intensity-Modulated 50 pembrolizumab 49 luprolide acetate gel depot 49 Flutamide 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00427999 2016-11-21

INV342

Novartis

Phase 2 Completed

67 enrolled 6 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡